Corporate News, Science and Technology, Resource Download

NewslettersSep 30, 2026

Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001 PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities

NewslettersAug 31, 2026

Porton Reports H1 2026 Results Porton Appoints Dr. Yongli Zhong as Chief Scientific Officer Porton Appoints Yunxing Yin as Corporate Vice President to Strengthen Small-Molecule R&D Leadership

NewslettersJul 31, 2026

Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control Porton Named as a Constituent of the FTSE4Good Index Series

NewslettersJun 30, 2026

Porton Newsletter - June 2026 Recap

NewslettersMay 31, 2026

Porton Newsletter - May 2026 Recap

NewslettersApr 30, 2026

Porton Newsletter - April 2026 Recap

NewslettersMar 31, 2026

Porton Newsletter - March 2026 Recap

NewslettersFeb 28, 2026

Porton Newsletter - February 2026 Recap

NewslettersFeb 03, 2026

Porton Newsletter - January 2026 Recap